BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
asciminib Sensitive: A1 - Approval
|
asciminib Sensitive: A1 - Approval
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + nilotinib Sensitive: C3 – Early Trials
|
venetoclax + nilotinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + bosutinib Sensitive: C3 – Early Trials
|
venetoclax + bosutinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
AML
|
BCR-ABL1 mutation
|
AML
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
AML
|
BCR-ABL1 mutation
|
AML
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
ALL
|
BCR-ABL1 mutation
|
ALL
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|